EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Mutant IDH1 cooperates with NPM1c or FLT3 ITD to drive distinct myeloid diseases and molecular outcomes

Takashi Sakamoto iD, Julie Leca, Xin Zhang, Cem Meydan, Jonathan Foox, Parameswaran Ramachandran, Liam D Hendrikse, Wenjing Zhou, Thorsten Berger, Jerome Fortin, Steven M Chan, Ming-Feng Chiang und 20 weitere

Proceedings of the National Academy of Sciences · 2025

DOI: 10.1073/pnas.2415779122 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2025. Verfasst von Takashi Sakamoto und 31 weiteren Autor:innen. Beteiligte Einrichtung: Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada. Hauptthemen laut MEDLINE: Isocitrate Dehydrogenase, fms-Like Tyrosine Kinase 3, Nuclear Proteins, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIMH NIH HHS, Leukemia and Lymphoma Society (LLS), Vallee Foundation (The Vallee Foundation).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In human acute myeloid leukemia (AML), mutations of isocitrate dehydrogenase-1 ( IDH1 ) often co-occur with NPM1 mutations, and less frequently with FLT3 mutations. To investigate whether the effects of IDH1 mutation differ according to the specific co-occurring mutation, we generated two strains of double knock-in mutant mice. Idh1 R132H combined with Npm1c induced overt AML, whereas Idh1 R132H plus Flt3 ITD resulted in Flt3 ITD -driven myelo- or lymphoproliferation that was minimally affected by Idh1 R132H and rarely generated AML. Gene expression profiling revealed differences between Idh1 R132H ; Npm1c cells and Idh1 R132H ; Flt3 ITD cells and suggested altered heme metabolism and immune responses in the former. The profile of Idh1 R132H ; Npm1c cells corresponded to that of human IDH -mutated AML cells, particularly those resistant to inhibitors of mutant IDH. Compared to treatment with a menin inhibitor, IDH1-targeted therapy of Idh1 R132H ; Npm1c AML-bearing mice was less efficacious in improving cell differentiation and extending survival. The differential cooperation of Idh1 R132H with Npm1c vs. Flt3 ITD may have implications for the devising of subtype-specific treatments for human AML.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Isocitrate Dehydrogenasefms-Like Tyrosine Kinase 3Nuclear ProteinsLeukemia, Myeloid, AcuteMutationNucleophosminAnimalsMiceHumansGene Knock-In Techniques

Stichwörter der Autor:innen

FLT3IDH1NPM1acute myeloid leukemiapreclinical mouse model

Substanzen

Isocitrate DehydrogenaseNucleophosminfms-Like Tyrosine Kinase 3Nuclear ProteinsNpm1 protein, mouseNPM1 protein, humanIdh1 protein, mouseIDH1 protein, humanFlt3 protein, mouseFLT3 protein, human

Autor:innen und Institutionen

  • Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada.
  • Department of Hematology, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan.
  • BMP, Ecosystem, stemness and dynamic in cancer Laboratory, Centre de Recherche en Cancerologie de Lyon, UMR INSERM 1052 CNRS 5286, Centre Léon Bérard, Université Claude Bernard Lyon 1, Lyon 69008, France.
  • Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY 10065.
  • The HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud Institute for Computational Biomedicine, Weill Cornell Medicine, New York, NY 10065.
  • WorldQuant Initiative for Quantitative Prediction, Weill Cornell Medicine, New York, NY 10065.

ORCID-Profile: Takashi Sakamoto, Christopher E Mason, Mark D Minden, Tak W Mak

Förderung

  • NIMH NIH HHS
  • Leukemia and Lymphoma Society (LLS)
  • Vallee Foundation (The Vallee Foundation)
  • MEXT | Japan Society for the Promotion of Science (JSPS)
  • Starr Cancer Consortium
  • NCI NIH HHS
  • NIAID NIH HHS
  • WorldQuant Foundation

Zitieren

APA

Sakamoto, T., Leca, J., Zhang, X., Meydan, C., Foox, J., Ramachandran, P., Hendrikse, L. D., Zhou, W., Berger, T., Fortin, J., Chan, S. M., Chiang, M. F., Inoue, S., Li, W. Y., Chu, M. F., Duncan, G. S., Wakeham, A., Lemonnier, F., Tobin, C., …, & Mak, T. W. (2025). Mutant IDH1 cooperates with NPM1c or FLT3 ITD to drive distinct myeloid diseases and molecular outcomes. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2415779122

Vancouver

Sakamoto T, Leca J, Zhang X, Meydan C, Foox J, Ramachandran P, et al. Mutant IDH1 cooperates with NPM1c or FLT3 ITD to drive distinct myeloid diseases and molecular outcomes. Proceedings of the National Academy of Sciences. 2025. doi:10.1073/pnas.2415779122

BibTeX
@article{Sakamoto2025,
  author = {Sakamoto, Takashi and Leca, Julie and Zhang, Xin and Meydan, Cem and Foox, Jonathan and Ramachandran, Parameswaran and Hendrikse, Liam D and Zhou, Wenjing and Berger, Thorsten and Fortin, Jerome and Chan, Steven M and Chiang, Ming-Feng and Inoue, Satoshi and Li, Wanda Y and Chu, Mandy F and Duncan, Gordon S and Wakeham, Andrew and Lemonnier, François and Tobin, Chantal and Mcwilliam, Ryan and Colonna, Isabelle and Bontoux, Christophe and Jafari, Soode Moghadas and Bowman, Robert L and Nicolay, Brandon and Ronseaux, Sebastien and Narayanaswamy, Rohini and Levine, Ross L and Melnick, Ari M and Mason, Christopher E and Minden, Mark D and Mak, Tak W},
  title = {Mutant IDH1 cooperates with NPM1c or FLT3 ITD to drive distinct myeloid diseases and molecular outcomes},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2025},
  doi = {10.1073/pnas.2415779122}
}
Kostenlos starten →